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Abstract
Objective: Mitochondrial dysfunction plays a key role in the pathophysiology
of neurodegenerative disorders such as ataxia and Parkinson’s disease. We
describe an extended Belgian pedigree where seven individuals presented with
adult-onset cerebellar ataxia, axonal peripheral ataxic neuropathy, and tremor,
in variable combination with parkinsonism, seizures, cognitive decline, and
ophthalmoplegia. We sought to identify the underlying molecular etiology and
characterize the mitochondrial pathophysiology of this neurological syndrome.
Methods: Clinical, neurophysiological, and neuroradiological evaluations were
conducted. Patient muscle and cultured fibroblasts underwent extensive analyses
to assess mitochondrial function. Genetic studies including genome-wide
sequencing were conducted. Results: Hallmarks of mitochondrial dysfunction
were present in patients’ tissues including ultrastructural anomalies of mito-
chondria, mosaic cytochrome c oxidase deficiency, and multiple mtDNA dele-
tions. We identified a splice acceptor variant in POLG2, c.970-1G>C,
segregating with disease in this family and associated with a concomitant
decrease in levels of POLG2 protein in patient cells. Interpretation: This work
extends the clinical spectrum of POLG2 deficiency to include an overwhelming,
adult-onset neurological syndrome that includes cerebellar syndrome, peripheral
neuropathy, tremor, and parkinsonism. We therefore suggest to include POLG2
sequencing in the evaluation of ataxia and sensory neuropathy in adults, espe-
cially when it is accompanied by tremor or parkinsonism with white matter dis-
ease. The demonstration that deletions of mtDNA resulting from autosomal-
dominant POLG2 variant lead to a monogenic neurodegenerative multicompo-
nent syndrome provides further evidence for a major role of mitochondrial dys-
function in the pathomechanism of nonsyndromic forms of the component
neurodegenerative disorders.
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Introduction
Mitochondrial dysfunction caused by disturbances of
mtDNA integrity gives rise to a diverse array of neurological,
neuromuscular, and multisystem disorders. The clonal
expansion of multiple mtDNA deletions is typically associ-
ated with late-onset primary mitochondrial disease charac-
terized by autosomal-dominant progressive external
ophthalmoplegia (adPEO) as the predominant clinical fea-
ture.1 MtDNA is replicated by the DNA polymerase gamma
complex, which is composed of a monomeric catalytic sub-
unit encoded by POLG and a dimeric accessory subunit
encoded by POLG2. Pathogenic POLG variants are a com-
mon cause of primary mitochondrial disorders typically
resulting in adPEO, but can also lead to a phenotypic spec-
trum manifesting variably across brain, muscle, and/or liver
(OMIM 157640, 258450, 203700, 613662, and 607459).
Few families have been reported to have disease due to
variants in POLG2. The first reported case of POLG2 disease
was documented in a patient with adult-onset autosomal
dominant PEO in whom multiple mtDNA deletions were
detected.2 The second identified case of POLG2 disease was a
patient who developed ptosis at age 30, but not ophthalmo-
plegia, and proximal and distal myopathy in her late forties.
Muscle biopsy showed clonally expanded multiple mtDNA
deletions.3 This family included a brother who possessed the
same POLG2 variant and showed no signs of disease at age
57, indicating possible incomplete penetrance. Subse-
quently, three cases with pediatric-onset autosomal domi-
nant disease with varying phenotypes have been reported: a
young adult with disease onset of adPEO in late teens and
two unrelated infants presenting with hypotonia, seizures,
and liver disease.4 With only a small number of cases
reported, it is clearly evident that POLG2-related disorders
display a spectrum of clinical phenotypes with a wide range
of age of onset.
We describe a severe neurological syndrome in a large
family with cerebellar ataxia, axonal sensory ataxic neu-
ropathy, and tremor. Some subjects also presented with
parkinsonism, seizures, cognitive decline, and ophthalmo-
plegia. Most died within 15 years of onset of clinical
symptoms of disease. Genetic studies revealed a POLG2
splice acceptor variant segregating with disease, leading to
loss of POLG2 protein in patient cells. This work extends
the clinical spectrum observed with POLG2 disease and
lends further support for the role of the accumulation of
mtDNA deletions in neurodegeneration.
Materials and Methods
Muscle histopathology and mtDNA analyses
Cryostat sections (10 lm) were cut from transversely
orientated muscle blocks and subjected to standard histo-
logical and histochemical analysis including COX, succi-
nate dehydrogenase (SDH), and sequential COX-SDH
oxidative enzyme reactions. Large-scale mtDNA rear-
rangements within the major arc were screened by long-
range PCR to amplify a ~13.0 kb product in wild-type
mtDNA (primers: NC_012920.1 chrM:129-110,
chrM:3965-3984). The level of deleted mtDNA in individ-
ual muscle fibers isolated by laser microcapture was
determined by quantitative real-time PCR using the ABI
PRISM Step One real-time PCR System (Life
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Technologies, Paisley, UK) to confirm the presence of
clonally expanded mtDNA deletions.5
Whole exome sequencing and bioinformatic
analyses
Whole exome sequencing was performed using Illumina
paired-end precapture libraries constructed according to
manufacturer’s protocol. Sequence data were aligned,
variants were called by GATK, and custom Perl scripts
were used to annotate variants as previously described.6
Multiple metrics for prediction of potential functional
consequences of variants were applied: CADD,7 Geno-
mic Evolutionary Rate Profiling (GERP),8 and PhyloP.
The Exome Aggregation Consortium (ExAC) Cohort
was used as reference population data (http://
exac.broadinstitute.org, accessed January, 2016). All
genetic alleles studied were annotated in reference to
POLG2 NM_007215.
Western blotting
Fibroblasts were grown in DMEM High Glucose with L-Glu-
tamine and Sodium pyruvate (Hyclone, ThermoFisherScien-
tific) with 15% FBS. Crude mitochondrial fraction was
prepared from 1 9 107 cells following Graham & Rickwood
method.9 Mitochondrial fractions were lysed in RIPA buffer
containing 50 mm Tris, pH 8.0, 150 mm NaCl, 0.5% sodium
deoxycholate, 1% Triton X-100, 0.1% SDS, 5 mg/mL leu-
peptin, 2 mg/mL aprotinin, and 0.5 mmol/L PMSF.
Thirty milligram of mitochondrial lysates were resolved on
SDS-polyacrylamide gel electrophoresis and transferred to a
0.45-mm PVDF membrane (Millipore). Western blotting was
performed as previously described.4
Reverse Transcription Quantitative PCR
RNA extraction was performed using TRIzol and purified
using PureLink RNA minikit (Life Technologies). First-
strand cDNA synthesis was done using SuperScript III
First-Strand Synthesis System for RT-PCR (Life Technolo-
gies) and oligodT. Quantitative RT-PCR experiments were
performed using StepOne Plus RT-PCR system (Applied
Biosystems). POLG2 oligonucleotides: forward 50AAACC
CTGTGGAACCTAGGAG30 and reverse 50AGCATGCCT
CGGTCTAGGTC30. Each sample was run in triplicate
and was normalized to GAPDH.
Membrane potential
Fibroblasts were grown on glass chamber slides and trea-
ted with 30 ng/mL rotenone for 4 h at 37°C, or the
same volume of solvent. 5,50,6,60-
tetraethylbenzimidazolyl-carbocyanine iodide (JC-1, Life
Sciences) of 5 lg/mL was added, and the cells were
incubated for 30 min at 37°C. Membrane potential was
determined by the ratio of red/green fluorescence in
eight random 4009 microscopic fields and expressed as
mean  standard deviation (SD).
Consent for the study was obtained from all subjects
and a local ethics review board approved the study.
Results
Clinical presentation
Seven native Belgian individuals from two sibships belong-
ing to the same extended family presented with a neurolog-
ical disorder involving cerebellar and sensory ataxia with
tremor (Fig. 1). Initial signs of disease rose to clinical atten-
tion between 50 and 77 years of age and in most cases
resulted in loss of life in less than 15 years from onset
(Table 1). Peripheral neuropathy developed in all individu-
als either concomitant with the cerebellar syndrome or
manifesting up to 6 years postonset of disease. Additional
features of disease in some individuals included epilepsy,
cognitive decline, ophthalmoplegia, hearing loss, and
parkinsonism. An overview of clinical and paraclinical signs
is presented in Table 1 and is summarized as follows.
Cerebellar ataxia, sensory neuropathy, and
action tremor
Patient II-1, presented at age 53 with gait disturbances.
He experienced both cerebellar and sensory ataxia, pro-
gressing within 6 years to a loss of ambulation. Addition-
ally, he experienced head tremor followed closely by an
arm tremor that was both intentional and resting. Elec-
trophysiological studies, comprised of recordings of nerve
conduction velocities (NCV), electromyography (EMG),
and somesthesic-evoked potentials (SEPs) indicated an
axonal sensorimotor neuropathy in the lower limbs, and
a pure sensory neuropathy of upper limbs. SEPs indicated
a near-absent spinal response and a very low-amplitude
cortical response. Patients II-8, II-11, II-12, II-13, and II-
17 showed similar clinical signs and courses with details
shown in Table 1. Available results from electrophysiology
studies for all subjects are shown in Table S1.
Parkinsonism
One subject, II-10, displayed a significantly different clini-
cal presentation and clinical course compared to the rest
of the kinship. Her disease presented at age 77 years, two
decades later than most others in this family, when she
received a diagnosis of asymmetrical Parkinson’s disease
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based on the onset of a resting tremor of the left hand,
mild left-sided rigidity, generalized akinesia (right<left),
hypomimia, head tremor, mild reduction in stride length,
reduced arm swing, and mild dystonic movements of the
left foot. While mild tandem ataxia was observed, notably,
patient II-10 had no sensory complaint at the onset of
symptoms and NCV and brain MRI were normal. In a 5-
year follow-up exam, only moderate reduction in palles-
thesia of lower limbs was noted, whereas NCV and MRI
were not repeated. This subject’s parkinsonian symptoms
improved with levodopa treatment.
Two additional patients displayed parkinsonism in
combination with ataxia and peripheral neuropathy as
described above. Patients II-13 and II-17 had bilateral
bradykinesia, reduced postural reflexes, and facilitory
paratonia without resting tremor or cogwheel rigidity at
the onset of their illness. In contrast to subject II-10, these
parkinsonian symptoms did not respond to levodopa.
Seizures and cognitive impairment
Five patients (II-1, II-11, II-12, II-13, and II-17) devel-
oped progressive cognitive impairment of the frontal-sub-
cortical subtype leading to profound dementia in two of
them (III, 11 and III, 17). The three males II-1, II-11, and
II-12 had a rapidly progressive cognitive decline followed
by generalized tonic-clonic seizures a few months before
death in status epilepticus at the end of their seventh dec-
ade. Two females II-8 and II-17 had isolated episodes of
generalized tonic-clonic seizures a few years after the
onset of their symptoms.
Ophthalmologic manifestations
Two patients displayed ophthalmological signs. Patient II-
17 showed classic hallmarks of PEO with ptosis but no
nystagmus, at age 59. By the age of 68, oculomotor exam-
ination revealed ophthalmoplegia with moderate limita-
tion of amplitude and marked slowness of horizontal and
vertical saccades and pursuit movements. Patient II-13
had moderate ophthalmoparesis without ptosis at 72. It is
noteworthy that the age of onset of this patient’s ophthal-
mologic dysfunction was beyond the age of death of most
affected subjects in this family.
Brain MRI reveals cortical and cerebellar
atrophy with cerebellar and brainstem
hypersignals
Affected individuals displayed cerebellar and brainstem
abnormalities on T2-Weighted and T2 FLAIR images with
focal hyperintense lesions of middle and upper cerebellar
peduncles, posterior area of the pons and mesencephalon
(medial longitudinal fasciculus), and the periaqueductal
grey matter. They also exhibited various degrees of multi-
focal hyperintense hemispheric white matter lesions, corti-
cal atrophy, and pontocerebellar atrophy (Fig. 1). Patient
II-8 had a normal MRI at the onset of symptoms. How-
ever, a second MRI performed 6 years later showed the
appearance of T2 and FLAIR diffuse hypersignals at the
level of middle cerebellar peduncles and midbrain and
cerebellar cortical atrophy, similar to those observed in
other affected family members.
Patient muscle shows signatures of
mitochondrial dysfunction including
multiple mtDNA deletions
Skeletal muscle biopsies from four affected individuals
were examined for evidence of mitochondrial dysfunction.
Electron microscopy ultrastructural studies revealed sev-
eral anomalies including subsarcolemmal accumulation of
abnormal mitochondria with paracrystalline inclusions
(Fig. 2A). Histopathological studies exhibited evidence of
subsarcolemmal mitochondrial accumulation as ragged-
blue fibers following SDH enzyme histochemistry,
whereas sequential COX-SDH histochemistry revealed a
mosaic pattern of COX deficiency, with preserved SDH
activity, in all four patients (Fig. 2B). Interestingly, there
was variability in severity of the associated COX defect
with 25% COX-deficient fibers and 5% ragged-red fibers
observed in patient II-8, whereas patient II-10 showed
milder changes with only 2% COX-deficient fibers and
1% ragged-red fibers (Fig. 2B), correlating with disease
severity.
Molecular studies revealed that muscle from all four
patients studied showed evidence of multiple mtDNA
deletions (Fig. 2C). Single muscle fibers were investigated
to characterize the presence of clonally expanded mtDNA
deletions, demonstrating that the majority of COX-
Figure 1. Pedigree and MRIs for family segregating POLG2 c.970-1G>C variant. Affected individuals are represented as black symbols, whereas
unaffected are open symbols. The genotype for the POLG2 c.970-1G>C variant is indicated for individuals who were genotyped. Brain MRIs
reveal abnormalities of the cerebellum and brain stem and white matter lesions. Axial T2-weighted images revealed bilateral hyperintense lesions
of (A) middle cerebellar peduncles, (B) upper cerebellar peduncles, and (C) periaqueductal grey matter in patients II-8, II-11, II-12, and II-13. Also
shown are the following: II-8 (D) Sagittal T2 image demonstrating mild supra and infratentorial atrophylenticular nuclei; II-11 (D) Axial T2 image
showing hypersignal of medial longitudinal fasciculus; II-12 (D) Axial T2 image showing important hemispheric atrophy and periventricular white
matter lesion; and II-13 (D) Sagittal T1 image demonstrating moderate pontocerebellar and supratentorial atrophy.
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deficient fibers revealed very high levels (>80% mutated
mtDNA) of clonally expanded mtDNA deletion, whereas
all COX-positive reacting fibers apart from one had levels
of mtDNA deletion below this level (Fig. 2D).
Genetic studies reveal POLG2 c.970-1G>C
heterozygous variant segregates with
disease
Whole-exome sequencing identified a heterozygous splice
variant, POLG2 c.970-1G>C, in affected individual II-17.
Variants in POLG2 are known to cause multiple mtDNA
deletions which was one of the molecular phenotypes
observed in muscle biopsy from our patients. The POLG2
c.970-1 G>C variant has not been previously reported in
the POLG2 disease literature and is not present in ExAC
database. Sequencing of family members confirmed
POLG2 c.970-1G>C segregated with disease in this pedi-
gree (Fig. 1).
POLG2 displays reduced RNA and protein
levels in patient fibroblasts
The pathogenic potential of the POLG2 variant was tested
through measuring the levels of POLG2 RNA and protein
in patient cells. The POLG2 c.970-1G>C variant is located
in the intron 4 splice acceptor site and predicted to cause
skipping of exon 5. Improper splicing of a transcript may
trigger nonsense-mediated decay or nonsense-associated
splicing and result in reduced levels of mRNA and pro-
tein. Reduced amounts of POLG2 mRNA were detected
in both patient fibroblast cell lines tested (Fig. 3A).
POLG2 protein levels in patient cells were 40% lower
than levels in healthy control cells (Fig. 3B and C). To
our knowledge this is the first example of a POLG2 vari-
ant causing reduction in protein levels. This drastic
reduction in POLG2 protein is likely the cause of the
mtDNA deletions detected (Fig. 2C and D) and the
pathological symptoms.
Patient fibroblasts show deficiencies in
mitochondrial membrane potential
Patient fibroblasts demonstrate a substantial reduction in
mitochondrial membrane potential (Fig. 3D–I). Mem-
brane potential was 2.18  0.44 in controls (mean 
SD), whereas patients showed a substantial reduction to
1.45  0.34 in II-1, 1.71  0.34 in II-10, and
1.61  0.31 in II-17. Notably, these results reveal a reduc-
tion in mitochondrial membrane potential concordant
with severity of patient clinical presentation. Inhibition of
complex I activity depresses membrane potential and
causes intracellular movement of the mitochondria
Table 1. An overview of clinical characteristics.
Subject ID
(II-1) (II-8) (II-10) (II-11) (II-12) (II-13) (II-17)
POLG2
c.970-1G>C
+ + + NA NA + +
Gender M F F M M F F
Age at onset 53 51 77 61 60 61 56
Age at death 68 Alive
69
Alive
83
69 68 77 Alive
68
Cerebellar
syndrome,
age at onset
50 52 77 61 60 61 56
Postural and
action tremor
+ + 77 61 63 63 56
Head tremor 60 55 77  >66 65 58
Cerebellar
ataxia
+ + 77 61 60 61 58
Dysmetria  67 63 71 58
Peripheral
nervous
system, age
at onset
50 52 80 67 60 61 57
Sensory loss + + 80 67 63 67 57
Areflexia, deep
tendon
+ +  67 63 67 57
Sensory ataxia + +  67 63 61 57
Neuropathic pain     60  
Parkinsonism,
age at onset
  77   65 57
Bradykinesia   77   65 57
Rest tremor   77    59
Rigidity   77   74 69
Postural
Instability
  77   67 57
Foot dystonia   77   71 59
Epileptic
seizures
+ +  69 63  59
Myoclonus    69 63  
Cognitive
impairment
+   68 >66 61 57
Ophthalmoplegia      61 59
Ptosis       58
Hearing loss     64 67 
Nerve conduction
studies
Sensory axonal
neuropathy
+ +  + + + +
Motor axonal
neuropathy
+   +   
MRI hypersignals
of brain stem,
cerebellum,
hemispheric
white matter
+ +  + + + +
Muscle biopsy:
mosaic
COX defect
+ + + NA NA NA +
Multiple
mtDNA
deletions
+ + + NA NA NA +
NA, Not Available.
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Figure 2. Electron microscopy, histochemistry, and mtDNA analyses in patient muscle show signs of mitochondrial dysfunction. (A) Electron microscopy of
Patient II-1 skeletal muscle reveals subsarcolemmal accumulation of abnormal mitochondria with paracrystalline inclusions. The general region of
subsarcolemnal accumulation is indicatedwith a black bracket and a black arrow points to one of the paracrystalline inclusions. (B) Sequential COX succinate
dehydrogenase (SDH) histochemistry demonstrates a mosaic distribution of COX-deficient muscle fibers (blue) among fibers exhibiting normal COX activity
(brown). Illustrated are the images for Patients II-1, II-17, II-8, and II-10. (C) Long-range PCR across the major mtDNA shows evidence of variable mtDNA
deletions in muscle from patients II-1, II-17, II-8, and II-10. The black bracket indicates the region of the gel where deletion fragments segregate. (D)
Quantitative, single-fiber real-time PCR reveals the majority—but not all—of COX-deficient fibers contain high levels of a clonally expandedmtDNA deletion
involving theMTND4 gene (36COX-positive and 36COX-deficient fibers laser captured from the biopsymaterial of patients II-1, II-8, and II-17).
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toward the nucleus, thus further exposing bioenergetics
defects. Upon addition of rotenone, a complex I inhibi-
tor, mitochondrial membrane potential shifted down in
controls and showed even greater deficits in patients’
cells. Notably, JC-1 staining showed variability in the
extent of green to red across individual cells, roughly cor-
relating with severity of disease (Fig. 3D–I). This mosaic
pattern of staining across cells has been previously
observed in primary mitochondrial disease patients with
combined OXPHOS deficiency due to an underlying
molecular etiology that results in a variable mutational
load in mtDNA across patient cells.10 To our knowledge
this is the first demonstration of this staining pattern in
cells from patients with a POLG2 pathogenic variant as
well as the first documentation of this pattern in any
patient with multiple mtDNA deletions.
Variable expressivity and the possibility of
reduced penetrance
The four founders in this pedigree were not available for
participation in this study as all were deceased. The
mother of the first sibship (I-2) and the father of the sec-
ond sibship (I-3) were siblings (Fig. 1). Likewise, the
father of the first sibship (I-1) and mother of the second
sibship (I-4) were siblings. Of these four individuals only
one, I-3, was noted by surviving family members as hav-
ing a neurological disorder. This individual received a
diagnosis of Parkinson’s disease at the age of 70 and died
at the age of 79. This makes I-3 the likeliest carrier of the
POLG2 c.970-1G>C variant among the four founders,
which obligates I-2 as a carrier as well. Individual I-2
reportedly died in ‘older age’ without signs of neurologi-
cal disease, raising the possibility of incomplete pene-
trance of this variant. However, all members of the
second generation of the pedigree who were available for
genotyping have genotypes that correspond to full pene-
trance of the variant, this included eight individuals who
were asymptomatic and did not possess the variant. Addi-
tionally, the oldest age of disease onset in this family is
77 and at the most recent clinic visit this subject II-10, at
age 82, was the oldest symptomatic person in this study
and manifested the mildest form of disease with parkin-
sonism, cerebellar ataxia, and sensory loss. This suggests
that variable expressivity may present with this variant, as
is not uncommon with POLG disease-causing variants.
Low levels of inherited heteroplasmic mutations of
mtDNA appear to accelerate the accumulation of somatic
mutation in mtDNA11 and this may influence variable
ages of onset of clinical presentation across individuals
carrying the same mutation.
Discussion
We describe a neurological syndrome comprised of cere-
bellar ataxia, axonal sensory ataxic neuropathy, and tre-
mor in combination with epileptic seizures, cognitive
decline, parkinsonism, and ophthalmoplegia. Brain imag-
ing studies indicated cerebellar and brainstem atrophy.
Genetic studies identified a heterozygous POLG2 splice
acceptor variant, c.970-1G>C, segregating with disease
that caused diminished levels of POLG2 mRNA and pro-
tein in patient tissue. To our knowledge this is the first
example of a POLG2 variant causing reduction in protein
levels. The clinical signs in this family are distinct from
previously reported cases of POLG2 deficiency and the
syndrome described here extends the POLG2-related phe-
notypic spectrum.
Recent microscopy reveals that POLG2 expression and
subcellular localization is critical for mtDNA replication.12
Autosomal dominant nonsynonymous point mutations in
POLG2 have previously been shown to cause late-onset
PEO with mtDNA deletions.2, 13 While total reduction in
POLG2 is embryonic lethal, 14 a reduction in POLG2 by
siRNA causes a 50% reduction in mtDNA in only
6 days.15 Mutations that affect splicing and expression in
POLG2 have previously been described by Walter et al.
2010.3 In that patient, a heterozygous 24 bp in-frame
insertion was identified that caused skipping of exon 7
and degradation of the POLG2 message affecting overall
POLG2 expression. This reduction in POLG2 expression
was associated with late-onset ptosis and myopathy. Thus,
the c.970-1G>C splice acceptor variant in POLG2 we
identified that causes reduction in POLG2 expression is
Figure 3. POLG2 mRNA and protein levels and mitochondrial membrane potential are decreased in patient fibroblasts. The level of POLG2 RNA
and protein was measured in control (C) and patient cells (II-10 and II-17). (A) Quantitative real-time PCR experiments were performed for human
GAPDH and POLG2 and expressed as a relative quantitation of POLG2/GAPDH. (B) Mitochondrial lysates were analyzed by Western blotting using
a rabbit polyclonal antisera raised against the recombinant human POLG2 protein. POLG2 is represented by the top band visible migrating at 55
kilodaltons (kDa), while two additional lower bands represent nonspecific binding. The black arrow points to the POLG2 band to help distinguish
it from the nonspecific bands. (C) Relative quantitation of protein was measured by comparing the intensity of POLG2 and MTCO1 bands in
controls and patients. D-I. JC-1 fluorescence studies of patient fibroblasts show reduced mitochondrial membrane potential. Imaging visualized
mitochondria with inactive (green) or active (red) membrane potential. Membrane potential was assessed in untreated (D, F, H) and rotenone-
treated (E, G, I) fibroblast cells. Control fibroblasts are shown in D, E; Patient II-1 fibroblast in F, G; Patient II-17 fibroblast in H, I. A mosaic
staining pattern of individual cells is present in patient fibroblasts, with some cells displaying predominantly red staining indicative of active
mitochondria in these cells (these cells are marked with a white asterisk).
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consistent with previous POLG2 mutations causing
mtDNA deletions and late-onset mitochondrial disease.
Like POLG2 mutations, other genetic causes of primary
multiple mtDNA deletion syndromes most often present as
adPEO with myopathy, but also manifest a broad range of
age of onset with variable phenotypes and expressivity. The
neurological syndrome described here shares some similari-
ties in clinical presentation with a POLG-related syndrome,
sensory ataxic neuropathy, dysarthria, and ophthalmopare-
sis (SANDO).16 SANDO may be distinguished from this
disorder by age of onset as it typically starts in childhood or
early adulthood and by the inclusion of dysarthria in the
SANDO clinical presentation. Likewise, variants in another
member of the mtDNA replication complex, C10orf2, can
lead to an ataxia-neuropathy syndrome that includes
dementia.17 Parkinsonism is a clinical feature of the neuro-
logical syndrome described here that is not commonly
reported in conjunction with multiple mtDNA deletions,
however, variants in POLG,18,19 C10orf2,20 OPA1,21 and
MPV1722 have been associated with neurological syn-
dromes that include parkinsonism as a component.
A thorough consideration of diseases included in the dif-
ferential diagnosis is particularly relevant given the demon-
strated variable expressivity of this variant and others
leading to similar phenotypes. Among additional neurolog-
ical syndromes that overlap with this disorder, but do not
have a primary mitochondrial etiology, a special attention
should be paid to Fragile X-associated tremor/ataxia syn-
drome (FXTAS), as it includes a similar age of onset with
progressive intention tremor, parkinsonism, cognitive
decline, and generalized cortical atrophy and hypersignals
in the middle cerebellar peduncles on MRI.23 Taking into
consideration these similarities, we suggest considering
POLG2 deficiency in the differential diagnosis for cases of
ataxia and sensory neuropathy in adults, especially when it
is accompanied by tremor or parkinsonism with white mat-
ter disease.
The mtDNA deletions identified in the patients’ tissues
in this study result from faulty replication of the mitochon-
drial genome due to the germline transmission of a genetic
variant, POLG2 c.970-1G>C, that likely results in reduced
efficacy of the mtDNA polymerase. mtDNA deletions may
also occur in the tissues of individuals without a primary
mitochondrial disorder through DNA damage induced by
ROS coupled with improper repair24 or through faulty
replication.25 As a result, mtDNA deletions along with a
corresponding mosaic COX deficiency pattern and single-
cell clonal expansion of mtDNA deletions have also been
observed in aged tissues of healthy individuals as well as in
tissues from patients with neurodegeneration that is not
due to a primary mitochondrial disorder. A relatively high
level of deleted mtDNA has been observed in substantia
nigra neurons from both aged controls and individuals
with Parkinson’s disease (67% of COX-deficient fibers).26
Some extent of mutant mtDNA in a cell can seemingly be
tolerated without an apparent functional consequence. This
has been studied through multiple modes and end points
and generally a mutational load of 60–90% of mtDNA
molecules within a single cell must be mutated before func-
tional consequences are appreciated.27 In this study,
approximately 25% of patient muscle fibers tested were
COX deficient and of these individual fibers typically
showed >80% mutant mtDNA molecules. The germline
transmission of a pathogenic variant in a gene essential for
proper maintenance of the mitochondrial genome leads to
the accumulation of somatic mtDNA deletions which may
result in the same clinical end points, such as Parkinson’s
disease, as manifest in individuals who do not possess a
germline variant but rather have accumulated somatic
mtDNA deletions for other reasons (DNA damage induced
by ROS or faulty replication). These studies converge
around the fundamental concept of accumulation of
somatic mtDNA deletions playing a crucial role in the neu-
rological decline observed in brain aging and in Parkinson’s
disease, regardless of etiology.
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